A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor
- PMID:17478612
- DOI: 10.1124/mol.106.033746
A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor
Abstract
THRX-160209 is a potent antagonist at the M(2) muscarinic acetylcholine (ACh) receptor subtype that was designed using a multivalent strategy, simultaneously targeting the orthosteric site and a nearby site known to bind allosteric ligands. In this report, we describe three characteristics of THRX-160209 binding that are consistent with a multivalent interaction: 1) an apparent affinity of the multivalent ligand for the M2 receptor subtype (apparent pK(I) = 9.51 +/- 0.22) that was several orders of magnitude greater than its two monovalent components (apparent pK(I) values < 6.0), 2) specificity of THRX-160209 for the M2 receptor subtype compared with the closely related M4 (apparent pK(I) = 8.78 +/- 0.24) and M1, M3, and M5 receptors (apparent pK(I) values <or= 8.0), and 3) acceleration (>10-fold) of the dissociation rate of tritium-labeled THRX-160209 from M2 receptors by competing monovalent ligands that are known to interact with either the orthosteric site (e.g., atropine) or a well characterized allosteric site (e.g., obidoxime) on the receptor. In complementary kinetic studies assessing allosteric modulation of the receptor, unlabeled THRX-160209 retarded dissociation of [3H]N-methyl scopolamine (NMS). The effects of THRX-160209 on retardation of [3H]NMS dissociation were competitively inhibited by obidoxime, suggesting that obidoxime and THRX-160209 bind to an overlapping region coincident with other typical muscarinic allosteric agents, such as 3-methyl-5-[7-[4-[(4S)-4-methyl-1,3-oxazolidin-2-yl]phenoxy]heptyl]-1,2-oxazole (W84) and gallamine. Taken together, these data are consistent with the hypothesis that THRX-160209 binds in a multivalent manner to the M2 receptor, simultaneously occupying the orthosteric site and a spatially distinct allosteric site.
Similar articles
- THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner.Steinfeld T, Hughes AD, Klein U, Smith JA, Mammen M.Steinfeld T, et al.Mol Pharmacol. 2011 Mar;79(3):389-99. doi: 10.1124/mol.110.069120. Epub 2010 Dec 7.Mol Pharmacol. 2011.PMID:21139051
- Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.Tränkle C, Weyand O, Voigtländer U, Mynett A, Lazareno S, Birdsall NJ, Mohr K.Tränkle C, et al.Mol Pharmacol. 2003 Jul;64(1):180-90. doi: 10.1124/mol.64.1.180.Mol Pharmacol. 2003.PMID:12815174
- Divergent modes of action among cationic allosteric modulators of muscarinic M2 receptors.Tränkle C, Mohr K.Tränkle C, et al.Mol Pharmacol. 1997 Apr;51(4):674-82. doi: 10.1124/mol.51.4.674.Mol Pharmacol. 1997.PMID:9106634
- Depressing time: Waiting, melancholia, and the psychoanalytic practice of care.Salisbury L, Baraitser L.Salisbury L, et al.In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5.In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5.PMID:36137063Free Books & Documents.Review.
- Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R.Bryant A, et al.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.Cochrane Database Syst Rev. 2022.PMID:36161421Free PMC article.Review.
Cited by
- Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors.Feng Z, Hu G, Ma S, Xie XQ.Feng Z, et al.AAPS J. 2015 Sep;17(5):1080-95. doi: 10.1208/s12248-015-9776-y. Epub 2015 May 5.AAPS J. 2015.PMID:25940084Free PMC article.Review.
- 2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.Newman AH, Battiti FO, Bonifazi A.Newman AH, et al.J Med Chem. 2020 Mar 12;63(5):1779-1797. doi: 10.1021/acs.jmedchem.9b01105. Epub 2019 Sep 24.J Med Chem. 2020.PMID:31499001Free PMC article.
- Orthosteric and Allosteric Dual Targeting of the Nuclear Receptor RORγt with a Bitopic Ligand.Meijer FA, Oerlemans GJM, Brunsveld L.Meijer FA, et al.ACS Chem Biol. 2021 Mar 19;16(3):510-519. doi: 10.1021/acschembio.0c00941. Epub 2021 Feb 17.ACS Chem Biol. 2021.PMID:33596047Free PMC article.
- Heterobivalent Inhibitors of Acetyl-CoA Carboxylase: Drug Target Residence Time and Time-Dependent Antibacterial Activity.Cifone MT, He Y, Basu R, Wang N, Davoodi S, Spagnuolo LA, Si Y, Daryaee T, Stivala CE, Walker SG, Tonge PJ.Cifone MT, et al.J Med Chem. 2022 Dec 22;65(24):16510-16525. doi: 10.1021/acs.jmedchem.2c01380. Epub 2022 Dec 2.J Med Chem. 2022.PMID:36459397Free PMC article.
- Novel Allosteric Modulators of G Protein-coupled Receptors.Gentry PR, Sexton PM, Christopoulos A.Gentry PR, et al.J Biol Chem. 2015 Aug 7;290(32):19478-88. doi: 10.1074/jbc.R115.662759. Epub 2015 Jun 22.J Biol Chem. 2015.PMID:26100627Free PMC article.Review.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases